Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium

Toji Miyagawa, Danielle Brushaber, Jeremy Syrjanen, Walter Kremers, Julie Fields, Leah K. Forsberg, Hilary W. Heuer, David Knopman, John Kornak, Adam Boxer, Howard J. Rosen, Bradley F Boeve, Brian Appleby, Yvette Bordelon, Jessica Bove, Patrick Brannelly, Christina Caso, Giovanni Coppola, Reilly Dever, Christina DheelBradford Dickerson, Susan Dickinson, Sophia Dominguez, Kimiko Domoto-Reilly, Kelley Faber, Jessica Ferrell, Ann Fishman, Jamie Fong, Tatiana Foroud, Ralitza Gavrilova, Debra Gearhart, Behnaz Ghazanfari, Nupur Ghoshal, Jill S. Goldman, Jonathan Graff-Radford, Neill Graff-Radford, Ian Grant, Murray Grossman, Dana Haley, Robin Hsiung, Edward Huey, David Irwin, David Jones, Lynne Jones, Kejal Kantarci, Anna Karydas, Daniel Kaufer, Diana Kerwin, Ruth Kraft, Joel Kramer, Walter Kukull, Irene Litvan, Diane Lucente, Codrin Lungu, Ian Mackenzie, Miranda Maldonado, Masood Manoochehri, Scott McGinnis, Emily McKinley, Mario F. Mendez, Bruce Miller, Namita Multani, Chiadi Onyike, Jaya Padmanabhan, Alexander Pantelyat, Rodney Pearlman, Leonard Petrucelli, Madeline Potter, Rosa V Rademakers, Eliana M. Ramos, Kate Rankin, Katya Rascovsky, Erik D. Roberson, Emily Rogalski, Pheth Sengdy, Leslie Shaw, Maria C. Tartaglia, Nadine Tatton, Joanne Taylor, Arthur Toga, John Q. Trojanowski, Ping Wang, Sandra Weintraub, Bonnie Wong, Zbigniew K Wszolek

Research output: Contribution to journalArticle

Abstract

Introduction: We created global rating scoring rules for the CDR® plus NACC FTLD to detect and track early frontotemporal lobar degeneration (FTLD) and to conduct clinical trials in FTLD. Methods: The CDR plus NACC FTLD rating was applied to 970 sporadic and familial participants from the baseline visit of Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL)/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS). Each of the eight domains of the CDR plus NACC FTLD was equally weighed in determining the global score. An interrater reliability study was completed for 40 participants. Results: The CDR plus NACC FTLD showed very good interrater reliability. It was especially useful in detecting clinical features of mild non-fluent/agrammatic variant primary progressive aphasia participants. Discussion: The global CDR plus NACC FTLD score could be an attractive outcome measure for clinical trials in symptomatic FTLD, and may be useful in natural history studies and clinical trials in FTLD spectrum disorders.

Original languageEnglish (US)
Pages (from-to)106-117
Number of pages12
JournalAlzheimer's and Dementia
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2020

Keywords

  • CDR
  • CDR plus NACC FTLD
  • behavior, comportment, and personality
  • frontotemporal lobar degeneration
  • global rating
  • language

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Utility of the global CDR<sup>®</sup> plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium'. Together they form a unique fingerprint.

  • Cite this

    Miyagawa, T., Brushaber, D., Syrjanen, J., Kremers, W., Fields, J., Forsberg, L. K., Heuer, H. W., Knopman, D., Kornak, J., Boxer, A., Rosen, H. J., Boeve, B. F., Appleby, B., Bordelon, Y., Bove, J., Brannelly, P., Caso, C., Coppola, G., Dever, R., ... Wszolek, Z. K. (2020). Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimer's and Dementia, 16(1), 106-117. https://doi.org/10.1002/alz.12033